Published in Mol Cancer Ther on August 23, 2011
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07
Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol (2015) 0.97
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget (2015) 0.92
Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep (2014) 0.92
Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res (2013) 0.92
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis (2013) 0.91
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol (2016) 0.90
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol (2013) 0.90
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget (2015) 0.87
Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. World J Gastroenterol (2014) 0.87
Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterol (2014) 0.86
The functional relevance of somatic synonymous mutations in melanoma and other cancers. Pigment Cell Melanoma Res (2015) 0.84
IL-1α expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. PLoS One (2013) 0.83
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs (2014) 0.83
Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis. World J Surg Oncol (2016) 0.82
Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One (2013) 0.81
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol (2015) 0.80
Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Cancer Med (2015) 0.80
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther (2016) 0.80
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer (2014) 0.79
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biol Ther (2012) 0.79
Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol (2012) 0.79
Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol (2014) 0.78
Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis. OMICS (2016) 0.75
Complexity of molecular alterations impacts pancreatic cancer prognosis. World J Gastrointest Oncol (2013) 0.75
Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol (2016) 0.75
Additional K-ras mutation analysis and Plectin-1 staining improve the diagnostic accuracy of pancreatic solid mass in EUS-guided fine needle aspiration. Oncotarget (2017) 0.75
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Br J Cancer (2017) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol (2011) 4.11
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.53
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol (2012) 3.44
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89
Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc (2006) 2.06
Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol (2004) 2.02
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
Early osteolysis following second-generation metal-on-metal hip replacement. J Bone Joint Surg Am (2005) 1.89
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma (2009) 1.83
Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst (2011) 1.77
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood (2007) 1.74
Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol (2004) 1.70
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66
Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J Hepatol (2005) 1.65
Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol (2007) 1.65
Novel interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean population. J Gastroenterol (2004) 1.65
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res (2006) 1.60
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer (2006) 1.56
Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis. PLoS One (2009) 1.55
Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology (2010) 1.55
Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology (2008) 1.52
NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology (2007) 1.52
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat (2009) 1.51
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol (2009) 1.50
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Onkologie (2011) 1.47
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 1.42
Which patients benefit from preoperative chemoradiotherapy for intermediate staged rectal cancer? Onkologie (2011) 1.42
Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology (2012) 1.42
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol (2013) 1.40
Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet (2008) 1.39
Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res (2007) 1.35
A prospective, comparative trial to optimize sampling techniques in EUS-guided FNA of solid pancreatic masses. Gastrointest Endosc (2013) 1.34
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol (2002) 1.34
Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol (2005) 1.34
High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One (2012) 1.32
Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer (2009) 1.31